Get the Stockscreener App
84.11
1.11%
-0.94
Pre-market:
83.44
-0.67
-0.80%
Dexcom Inc stock is traded at $84.11, with a volume of 5.20M.
It is down -1.11% in the last 24 hours and up +27.17% over the past month.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
See More
Previous Close:
$85.05
Open:
$84.74
24h Volume:
5.20M
Relative Volume:
1.18
Market Cap:
$31.97B
Revenue:
$4.15B
Net Income/Loss:
$535.20M
P/E Ratio:
62.77
EPS:
1.34
Net Cash Flow:
$575.20M
1W Performance:
+3.16%
1M Performance:
+27.17%
6M Performance:
+15.97%
1Y Performance:
-32.69%
1-Day Range:
$83.84
$85.54
1-Week Range:
$80.50
$87.02
52-Week Range:
$57.52
$132.26
Dexcom Inc Stock (DXCM) Company Profile
Name
Dexcom Inc
Sector
Industry
Phone
(858) 200-0200
Address
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
84.11 | 31.97B | 4.15B | 535.20M | 575.20M | 1.34 |
|
ABT
Abbott Laboratories
|
129.05 | 231.50B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.95 | 154.04B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
387.53 | 144.27B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
85.11 | 105.58B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
75.50 | 43.95B | 5.54B | 4.18B | 623.10M | 7.00 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-03-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Jan-16-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-26-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-24 | Initiated | Redburn Atlantic | Neutral |
| Mar-12-24 | Initiated | RBC Capital Mkts | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-17-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-29-23 | Initiated | UBS | Buy |
| Jan-26-23 | Initiated | Wolfe Research | Outperform |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-15-22 | Initiated | Bernstein | Outperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-07-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-18-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-28-21 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Jan-06-21 | Upgrade | UBS | Neutral → Buy |
| Oct-02-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| May-27-20 | Reiterated | Piper Sandler | Overweight |
| May-14-20 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Nov-07-19 | Reiterated | Canaccord Genuity | Buy |
| Nov-07-19 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-19 | Initiated | Stifel | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-19-18 | Upgrade | Goldman | Sell → Neutral |
| Sep-12-18 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Aug-02-18 | Reiterated | Canaccord Genuity | Buy |
| Jul-02-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-08-18 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-18 | Initiated | BofA/Merrill | Buy |
| May-03-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-04-18 | Initiated | Goldman | Sell |
| Apr-04-18 | Initiated | Guggenheim | Neutral |
| Mar-23-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-04-18 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Sep-28-17 | Reiterated | Wedbush | Outperform |
View All
Dexcom Inc Stock (DXCM) Latest News
DexCom, Inc. (DXCM) Announces Leadership Promotion: Jacob S. Lea - GuruFocus
DexCom (DXCM) Elevates Jake Leach to President - GuruFocus
Dexcom promotes Jake Leach to president role - MassDevice
The Zacks Analyst Blog Highlights Sprouts Farmers Market, DexCom, Hims & Hers Health, United Natural Foods and GoodRx - Yahoo Finance
Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO | DXCM Stock News - GuruFocus
Dexcom Promotes Jake Leach to Expanded President, COO Role - Medical Product Outsourcing
DexCom Adds President Role to COO Jake Leach - marketscreener.com
Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO - Business Wire
All You Need to Know About DexCom (DXCM) Rating Upgrade to Buy - Yahoo Finance
Buy 5 Health and Fitness Stocks to Enhance Your Portfolio Returns - TradingView
DexCom Stock: Earnings Beat and New Market Access Drive Bull Case - MSN
DXCM STOCK NOTICE: Did DexCom, Inc. Commit Securities Fraud? Investors are Urged to Contact BFA Law about its Investigation if You Suffered Losses (DXCM) - ACCESS Newswire
Investor Network: DexCom, Inc. to Host Earnings Call - ACCESS Newswire
DexCom, Inc. (DXCM) Announces Key Approvals at Annual Meeting - GuruFocus
Dexcom Stockholders Approve Equity Plan Amendments - TipRanks
DexCom Q1 Earnings: Organic Revenue Growth Versus Cost Pressure (NASDAQ:DXCM) - Seeking Alpha
Should You Investigate DexCom, Inc. (NASDAQ:DXCM) At US$85.34? - Yahoo Finance
Is DexCom, Inc. (DXCM) the Best Medical Device Stock to Buy Now? - Insider Monkey
Shareholders that lost money on DexCom, Inc.(DXCM) should contact Levi & Korsinsky about pending Class ActionDXCM - ACCESS Newswire
Class Action Filed Against DexCom, Inc. (DXCM) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Lost Money on DexCom, Inc. (DXCM)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of DexCom, Inc.(DXCM) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
DexCom, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before October 21, 2024 to Discuss Your RightsDXCM - ACCESS Newswire
Investors Who Lost Money on DexCom, Inc. (DXCM) Should Contact Levi & Korsinsky About Pending Class ActionDXCM - ACCESS Newswire
Shareholders that lost money on DexCom, Inc.(DXCM) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
DXCM FRAUD UPDATE: DexCom, Inc. Investors are Encouraged to Contact BFA Law before the Expiration of the October 21 Legal Deadline in Securities Fraud Case - ACCESS Newswire
DexCom, Inc. Class Action: Levi & Korsinsky Reminds DexCom Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 21, 2024DXCM - ACCESS Newswire
Shareholders of DexCom, Inc. Should Contact Levi & Korsinsky Before October 21, 2024 to Discuss Your RightsDXCM - ACCESS Newswire
Kessler Topaz Meltzer & Check, LLP Encourages DexCom, Inc. Investors with Losses to Contact the Firm - ACCESS Newswire
DexCom, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before October 21, 2024 to Discuss Your RightsDXCM - ACCESS Newswire
DexCom, Inc. (DXCM): A Bull Case Theory - Insider Monkey
Diabetes Dialogue: Dexcom G7, Libre App, and Medtronic Simplera Sync - HCPLive
Why DexCom Inc. (DXCM) Soared Last Week - MSN
William Blair Issues Negative Estimate for DexCom Earnings - Defense World
Oura, Dexcom Release Glucose App Linked with Stelo CGM - Medical Product Outsourcing
ŌURA rolls out glucose app linked with Dexcom’s CGM Stelo - Yahoo
Dexcom expands Oura partnership with Stelo integration - MassDevice
Your Oura Ring can now track meals and monitor glucose levels - Mashable
DexCom (NASDAQ:DXCM) Price Target Raised to $93.00 at Barclays - Defense World
Wait For A Dip To Buy DexCom Stock - Nasdaq
DexCom (DXCM) Gets Price Target Increase from Barclays | DXCM St - GuruFocus
Barclays Adjusts DexCom Price Target to $93 From $90, Maintains Equal Weight Rating - marketscreener.com
DexCom (DXCM) Gets Price Target Increase from Barclays | DXCM Stock News - GuruFocus
Should You Buy DXCM Stock At $80? - Forbes
Dexcom revenue grows 12% to USD 1.036 billion in Q1 2025 - Medical Buyer
Barclays Adjusts Price Target for DexCom (DXCM) to $93 Following Q1 Results | DXCM Stock News - GuruFocus
DexCom: Growth Is Reaccelerating But Don't Ignore The Risks - Seeking Alpha
DexCom (DXCM) Shares Surge on Strong Revenue and Buyback Announcement - GuruFocus
Dexcom Stock Is Today’s Big Winner After Earnings. Why the Medtech is Soaring. - Barron's
Duolingo, CoreWeave And DexCom Are Among Top 10 Large-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio? - Benzinga
DexCom Inc. stock outperforms competitors on strong trading day - MSN
Dexcom Inc Stock (DXCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.38%
0.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):